1286 related articles for article (PubMed ID: 32504925)
1. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?
Meini S; Zanichelli A; Sbrojavacca R; Iuri F; Roberts AT; Suffritti C; Tascini C
Front Immunol; 2020; 11():2014. PubMed ID: 32849666
[TBL] [Abstract][Full Text] [Related]
3. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
7. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
10. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
[TBL] [Abstract][Full Text] [Related]
11. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
[TBL] [Abstract][Full Text] [Related]
12. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
[No Abstract] [Full Text] [Related]
13. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
15. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
16. The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology.
Sohaei D; Hollenberg M; Janket SJ; Diamandis EP; Poda G; Prassas I
Crit Rev Clin Lab Sci; 2023 Jan; 60(1):25-40. PubMed ID: 35930434
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Garvin MR; Alvarez C; Miller JI; Prates ET; Walker AM; Amos BK; Mast AE; Justice A; Aronow B; Jacobson D
Elife; 2020 Jul; 9():. PubMed ID: 32633718
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
Groß S; Jahn C; Cushman S; Bär C; Thum T
J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703
[TBL] [Abstract][Full Text] [Related]
19. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
20. ACE2 and COVID-19 and the resulting ARDS.
Zhang X; Li S; Niu S
Postgrad Med J; 2020 Jul; 96(1137):403-407. PubMed ID: 32522846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]